Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-05-23
DOI
10.3389/fimmu.2022.886546
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
- (2022) J. Joseph Melenhorst et al. NATURE
- Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains
- (2022) Yupanun Wutti-in et al. Frontiers in Oncology
- Humanized CD30-Targeted Chimeric Antigen Receptor T Cells Exhibit Potent Preclinical Activity Against Hodgkin’s Lymphoma Cells
- (2022) Jing Guo et al. Frontiers in Cell and Developmental Biology
- Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma
- (2021) Agrima Mian et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Robust anti-tumor activity and low cytokine production by novel humanized anti-CD19 CAR-T cells
- (2021) Alka Dwivedi et al. MOLECULAR CANCER THERAPEUTICS
- Immunogenicity of CAR T cells in cancer therapy
- (2021) Dimitrios L. Wagner et al. Nature Reviews Clinical Oncology
- Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
- (2021) Darel Martínez Bedoya et al. Frontiers in Immunology
- Delivery technologies for T cell gene editing: Applications in cancer immunotherapy
- (2021) Ella S. Atsavapranee et al. EBioMedicine
- Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
- (2021) Regina M. Myers et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary safety and efficacy of PBCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product, in relapsed/refractory (r/r) CD19+ NHL.
- (2021) Bijal D. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
- (2021) Jesus G Berdeja et al. LANCET
- The antigen‐binding moiety in the driver's seat of CARs
- (2021) Heleen Hanssens et al. MEDICINAL RESEARCH REVIEWS
- Tisagenlecleucel Immunogenicity in Relapsed/Refractory Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma
- (2021) Karen Thudium Mueller et al. Blood Advances
- Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
- (2021) Caron A Jacobson et al. LANCET ONCOLOGY
- Autologous CAR T-cell therapies supply chain: challenges and opportunities?
- (2020) Maria M. Papathanasiou et al. CANCER GENE THERAPY
- Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
- (2020) Jennifer N. Brudno et al. NATURE MEDICINE
- ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
- (2020) S. Depil et al. NATURE REVIEWS DRUG DISCOVERY
- Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains
- (2020) Norris Lam et al. Nature Communications
- EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B‐Cell Lymphoma
- (2020) Irene Papadouli et al. ONCOLOGIST
- Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward
- (2020) Leila Jafarzadeh et al. Frontiers in Immunology
- CAR-T design: Elements and their synergistic function
- (2020) Jayapriya Jayaraman et al. EBioMedicine
- Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies
- (2020) Jordan Gauthier et al. BLOOD
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
- (2020) Reuben Benjamin et al. LANCET
- Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells
- (2019) Dwivedi Alka et al. Frontiers in Immunology
- Engineering and Design of Chimeric Antigen Receptors
- (2019) Sonia Guedan et al. Molecular Therapy-Methods & Clinical Development
- Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
- (2019) Mohamed-Reda Benmebarek et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer
- (2019) Steven Feins et al. AMERICAN JOURNAL OF HEMATOLOGY
- Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics
- (2019) Boris Gorovits et al. BIODRUGS
- Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
- (2019) Jie Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
- (2019) Stefan Stoiber et al. Cells
- Treatment with humanized selective CD19CAR-T cells shows efficacy in highly treated B-ALL patients who have relapsed after receiving murine-based CD19CAR-T therapies
- (2019) Yu Zhao et al. CLINICAL CANCER RESEARCH
- Phase 1 First-in-Human Study of AUTO2, the First Chimeric Antigen Receptor (CAR) T Cell Targeting APRIL for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
- (2019) Rakesh Popat et al. BLOOD
- Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients
- (2019) David A Sallman et al. BLOOD
- Sustained therapeutic efficacy of humanized anti-CD19 chimeric antigen receptor T cells in relapsed/refractory acute lymphoblastic leukemia
- (2019) Cheng Qian et al. CLINICAL CANCER RESEARCH
- Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
- (2019) Jiali Cheng et al. Frontiers in Oncology
- A generic cell surface ligand system for studying cell–cell recognition
- (2019) Eleanor M. Denham et al. PLOS BIOLOGY
- CAR T-cell Therapy: A New Era in Cancer Immunotherapy
- (2018) Miliotou N. Androulla et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
- (2018) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cytokine release syndrome
- (2018) Alexander Shimabukuro-Vornhagen et al. Journal for ImmunoTherapy of Cancer
- Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
- (2018) Timothy M. Pierpont et al. Frontiers in Oncology
- A phase I trial of T4 CAR T-cell immunotherapy in head and neck squamous cancer (HNSCC).
- (2018) Sophie Papa et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy
- (2018) Kevin A. Hay BRITISH JOURNAL OF HAEMATOLOGY
- A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
- (2018) Wan-Hong Zhao et al. Journal of Hematology & Oncology
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
- (2018) Susanne H. Baumeister et al. Cancer Immunology Research
- Fully human CD19-specific chimeric antigen receptors for T-cell therapy
- (2017) D Sommermeyer et al. LEUKEMIA
- Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains
- (2017) Leah Alabanza et al. MOLECULAR THERAPY
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
- (2017) Frederick L. Locke et al. MOLECULAR THERAPY
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
- (2017) Waseem Qasim et al. Science Translational Medicine
- Role of tumor microenvironment in tumorigenesis
- (2017) Maonan Wang et al. Journal of Cancer
- Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer
- (2017) Kristen M. Hege et al. Journal for ImmunoTherapy of Cancer
- Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview
- (2016) C. H. J. Lamers et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers
- (2016) Qiong J. Wang et al. CLINICAL CANCER RESEARCH
- Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target
- (2016) Alfredo Perales-Puchalt et al. CLINICAL CANCER RESEARCH
- Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
- (2016) Jiangtao Ren et al. CLINICAL CANCER RESEARCH
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34+ cells of juvenile myelomonocytic leukemia
- (2016) Yozo Nakazawa et al. Journal of Hematology & Oncology
- 247. Phase I Study of Second Generation Chimeric Antigen Receptor-Engineered T Cells Targeting IL13Rα2 for the Treatment of Glioblastoma
- (2016) Christine E. Brown et al. MOLECULAR THERAPY
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
- (2016) Christine E. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical manufacturing of CAR T cells: foundation of a promising therapy
- (2016) Xiuyan Wang et al. Molecular Therapy-Oncolytics
- Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies
- (2015) Laurent Poirot et al. CANCER RESEARCH
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy
- (2015) Julien Valton et al. MOLECULAR THERAPY
- Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma
- (2015) Laura A. Johnson et al. Science Translational Medicine
- The Global Burden of Cancer 2013
- (2015) Christina Fitzmaurice et al. JAMA Oncology
- Drug Resistance in Cancer: An Overview
- (2014) Genevieve Housman et al. Cancers
- Multicenter Analyses Demonstrate Significant Clinical Effects of Minor Histocompatibility Antigens on GvHD and GvL after HLA-Matched Related and Unrelated Hematopoietic Stem Cell Transplantation
- (2013) Eric Spierings et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Toward eliminating HLA class I expression to generate universal cells from allogeneic donors
- (2013) H. Torikai et al. BLOOD
- Cancer in developing countries: The next most preventable pandemic. The global problem of cancer
- (2013) Miriam López-Gómez et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Design and development of therapies using chimeric antigen receptor-expressing T cells
- (2013) Gianpietro Dotti et al. IMMUNOLOGICAL REVIEWS
- megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering
- (2013) Sandrine Boissel et al. NUCLEIC ACIDS RESEARCH
- The Basic Principles of Chimeric Antigen Receptor Design
- (2013) Michel Sadelain et al. Cancer Discovery
- T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
- (2013) M. V. Maus et al. Cancer Immunology Research
- A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR
- (2012) H. Torikai et al. BLOOD
- Genetically Modified T cells Targeting Interleukin-11 Receptor -Chain Kill Human Osteosarcoma Cells and Induce the Regression of Established Osteosarcoma Lung Metastases
- (2011) G. Huang et al. CANCER RESEARCH
- Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
- (2010) Michael C. Jensen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells
- (2010) C. H. J. Lamers et al. BLOOD
- The immunogenicity of humanized and fully human antibodies
- (2010) Fiona A. Harding et al. mAbs
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started